Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management

被引：9
作者：
Sundararajan, Srinath [1 ]
Kumar, Abhijeet [1 ]
Poongkunran, Mugilan [2 ]
Kannan, Arun [3 ]
Vogelzang, Nicholas J. [4 ,5 ]
机构：
[1] Univ Arizona, Dept Med, Div Hematol & Oncol, Tucson, AZ USA
[2] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
[3] Univ Arizona, Dept Med, Div Cardiol, Tucson, AZ USA
[4] Univ Nevada, Sch Med, Las Vegas, NV 89154 USA
[5] US Oncol, Comprehens Canc Ctr Nevada, Las Vegas, NV USA
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 08期
关键词：
adverse effects; angiogenesis inhibitors; anti-VEGF therapy; cardiovascular; tyrosine kinase inhibitors; ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; ARTERIAL THROMBOEMBOLIC EVENTS; TYROSINE-KINASE INHIBITORS; TO-DATE METAANALYSIS; RANDOMIZED PHASE-II; CANCER-PATIENTS; DOUBLE-BLIND; NITRIC-OXIDE; VENOUS THROMBOEMBOLISM;
D O I：
10.2217/fon.16.4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Anticancer treatment has evolved enormously over the last decade. Drugs targeting receptor tyrosine kinases, VEGFR and EGFR have changed the treatment landscape of certain cancers and have shifted the theme of anticancer therapy toward personalized care. However, these newer agents also come with unique side-effect profiles not seen with conventional chemotherapy including serious cardiovascular adverse effects. Hence, meticulous understanding of the adverse effects is crucial in maximizing clinical benefits and minimizing detrimental effects of these newer drugs. We have reviewed the cardiovascular adverse effects of anti-VEGF therapy in this article.
引用
收藏
页码：1067 / 1080
页数：14
相关论文
共 88 条
[1]   Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis [J].
An, Mao Mao ;
Zou, Zui ;
Shen, Hui ;
Liu, Ping ;
Chen, Meng Li ;
Cao, Yong Bing ;
Jiang, Yuan Ying .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (08) :813-821
[2]  
[Anonymous], 2012, VOTRIENT PAZ TABL PR
[3]  
[Anonymous], 2009, BEV PACK INS
[4]  
[Anonymous], 2015, FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood
[5]  
[Anonymous], 2010, AM SOC CLIN ONC S15S, V28
[6]   Vascular endothelial growth factors and vascular permeability [J].
Bates, David O. .
CARDIOVASCULAR RESEARCH, 2010, 87 (02) :262-271
[7]   Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study [J].
Burger, Robert A. ;
Sill, Michael W. ;
Monk, Bradley J. ;
Greer, Benjamin E. ;
Sorosky, Joel I. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5165-5171
[8]  
Choueri T., TOXICITY MOL TARGETE
[9]  
Cortes J KD, 2014, BLOOD, V124, pe494
[10]  
Cortes J SG, 2014, 56 ASH ANN M EXP SAN
123456789